Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Go back to Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality| (NASDAQ: EOLS) | Delayed: 7.86 -0.15 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.01 | 52 Week High | $ | |||
| Open | $8.00 | 52 Week Low | $ | |||
| Day High | $8.00 | P/E | N/A | |||
| Day Low | $7.81 | EPS | $ | |||
| Volume | 1,181,608 | |||||
